In Reply Dr Scarabin highlights our finding that menopausal hormone therapy use at study enrollment was not associated with incident VTE.1 At enrollment, women in the UK Biobank reported whether they had ever used menopausal hormone therapy, the age at which they started and (if applicable) stopped using therapy, and whether they were currently using hormones. In our postmenopausal cohort, it is unlikely that women who were never users of menopausal hormone therapy at enrollment subsequently started using it after the study began—particularly in the era following publication of the Women’s Health Initiative results.2 Women with any prevalent cardiovascular disease diagnoses at baseline, including VTE, were excluded from the analysis, and a secondary analysis evaluated development of a first VTE event.
Honigberg MC, Natarajan P. Premature Menopause and Risk for Cardiovascular Disease—Reply. JAMA. 2020;323(16):1617–1618. doi:10.1001/jama.2020.2536
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: